Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-110
SponsorScott C. Woller, MD

About this trial

A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to decrease their risk of blood clots, and for whom the risk of bleeding is minimal.

The purpose of this study is to evaluate the use of a pop-up alert, which will be seen by clinicians when a discharging patient has been identified as being someone for whom the risk of blood clots is high, but for whom bleeding risk is estimated to be low.

The pop-up alert will be enabled in a sequential fashion for each group of hospitals in 1 month blocks. We will look to see if the pop-up alert changes the number of patients who receive rivaroxaban. We will also measure the outcomes of blood clots and bleeding among all discharging patients.

Eligibility criteria

Qualifiers

Physician, nurse practitioner, or physician assistant hospitalist

Physician internal medicine

Physician family medicine

Patient age ≥ 18 years.

Disqualifiers

Pregnant during encounter

Discharge order completed by ineligible clinician type

Apixaban

Dabigatran

Trial design

Treatments tested in this trial

  • EHR (electronic health record) alert
  • No EHR (electronic health record) alert

Treatment groups

152,000 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Scott C. Woller, MD

Lead sponsor

Intermountain Health Care, Inc.

Sponsor institution

Janssen Pharmaceuticals

Collaborator